| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03736967 2018-001543-30 Details | 2021-11-01 Interventional | 2 | 206 | Antibodies, Mon… Dermatitis Dermatitis, Ato… Eczema Atopic Dermatit… | Lack of efficacy The decision was made by the sponsor to terminate the study on 12 Feb 2020 due to lack of efficacy. Study enrollment was not complete at that time, therefore planned sample sizes were not met. Participants discontinued study drug and transitioned into the post-treatment follow-up period. As a result of the decision to terminate the study, all statistical analyses were descriptive and no hypothesis testing was performed. | |||
| NCT03593109 Details | 2021-11-01 Interventional | 1 | 1 | Immunomodulatin… Lymphoma Lymphoma, B-Cel… | Suitable patients were not recruited - | |||
| NCT02555293 Details | 2021-11-01 Interventional | 2 | - | Rifaximin Liver Diseases Major Liver Res… Malignant Liver… | Prematurely terminated due to organisational reasons - | |||
| NCT04540848 Details | 2021-10-29 Interventional | 4 | 0 | Bupivacaine Pain, Postopera… Post Operative … | Lack of ability to communicate with the study population - | |||
| NCT04531592 Details | 2021-10-29 Interventional | 2 | 0 | Valproic Acid Acute Kidney In… Ischemia Reperfusion Inj… Wounds and Inju… Ischemia Reperf… | Study terminated by the Sponsor - | |||
| NCT04531579 Details | 2021-10-29 Interventional | 2 | 0 | Pharmaceutical … Valproic Acid Acute Kidney In… Ischemia Reperfusion Inj… Wounds and Inju… Ischemia Reperf… | Study terminated by the Sponsor. - | |||
| NCT03481842 Details | 2021-10-29 Interventional | 1/2 | 0 | Afatinib Axitinib Endometriosis Endometriosis E… Endometriosis O… Endometriosis, … | Change in study design and sponsor - | |||
| NCT02792192 Details | 2021-10-28 Interventional | 1/2 | 24 | Atezolizumab Non-Muscle Inva… Urinary Bladder… Bladder Cancer | The study was terminated early as the study had met its goals of providing preliminary safety
and efficacy information for atezolizumab monotherapy alone and in combination with BCG in
NMIBC. Participants were enrolled only in Cohort 1 of this study. The Sponsor decided not to enroll participants in Cohorts 2 and 3 after the enrollment of 24 patients in Cohort 1 (BCG-unresponsive cohort), as the study had met its goals of providing preliminary safety and efficacy information for atezolizumab monotherapy alone and in combination with BCG in NMIBC. | |||
| NCT01035658 Details | 2021-10-28 Interventional | 1/2 | 22 | Doxorubicin Liposomal doxor… Adenocarcinoma Fallopian Tube … Hypersensitivit… Fallopian Tube … Ovarian Cancer Peritoneal Carc… | Based on analyses in Phase I, the study did not advance to Phase II. Per protocol, study did not proceed to phase II based on analyses from phase I. Therefore, Phase II outcomes (all outcomes other than determination of the MTD) were not evaluated and will not be posted. | |||
| NCT04381988 Details | 2021-10-27 Interventional | 2 | 4 | Hydroxychloroqu… COVID-19 Cancer | The study was terminated based results of other studies and use of the new vaccine. - | |||
| NCT03504917 Details | 2021-10-27 Interventional | 3 | 322 | Balovaptan Autism Spectrum… Autistic Disord… Child Developme… | A futility analysis assessed that the study is highly unlikely to meet the pre-defined primary
objective of the study. No new safety concerns were identified. - | |||
| NCT03422094 Details | 2021-10-27 Interventional | 1 | 3 | Ipilimumab Nivolumab Poly ICLC Glioblastoma | Manufacturer changed focus to cell therapy - | |||
| NCT02563561 Details | 2021-10-27 Interventional | 3 | 62 | Apaziquone Urinary Bladder… Bladder Cancer | - The study was terminated as per Sponsor's decision. | |||
| NCT01960023 Details | 2021-10-27 Interventional | 1/2 | 0 | Cetuximab Neratinib Colorectal Neop… Colorectal Canc… | This registry was planned to report on the Phase II portion of the study. NSABP decided not to
proceed with the Phase II portion of the study. - | |||
| NCT03685344 2018-002670-43 Details | 2021-10-26 Interventional | 1 | 13 | Antibodies, Mon… Durvalumab Loncastuximab t… Lymphoma Lymphoma, B-Cel… Lymphoma, Folli… Lymphoma, Large… Lymphoma, Mantl… Diffuse Large B… Follicular Lymp… Mantle Cell Lym… | In a limited number of patients, no additional activity was evident for the combination vs.
loncastuximab tesirine monotherapy. - | |||
| NCT03581084 Details | 2021-10-26 Interventional | 4 | 1 | Acetylcysteine N-monoacetylcys… Asthma | The study was redesigned to be conducted in an outpatient setting. - | |||
| NCT02687451 Details | 2021-10-26 Interventional | 3 | 28 | Oxymorphone Acute Pain Pain, Postopera… Post-Operative … | Released from PMR - | |||
| NCT04958967 Details | 2021-10-25 Interventional | 1 | 0 | Aflutinib NSCLC | The protocol need to review - | |||
| NCT03467217 Details | 2021-10-21 Interventional | 2 | 83 | Losartan Fatty Liver Liver Diseases Non-alcoholic F… NAFLD - Nonalco… | Trial stopped for futility - | |||
| NCT03469050 2017-002708-28 Details | 2021-10-20 Interventional | 2/3 | 193 | Rifaximin Diverticulitis | Sponsor's decision - |